Abeille Pharmaceuticals, Inc. Licenses AB-1001 to SymBio Pharmaceuticals for Commercialization in Japan and Pacific Rim Countries
3/15/2007 10:49:33 AM
More...
|
Abeille Pharmaceuticals, Inc. Submits AB-1001 Phase III Pivotal Efficacy Study Protocol For FDA Review
8/9/2006 10:21:19 AM
More...
|
Abeille Pharmaceuticals, Inc. In-Licenses Worldwide Exclusive Rights To Technology For Transdermal Patch Applications
5/3/2006 12:14:45 PM
More...
|
Abeille Pharmaceuticals, Inc. Initiates Phase I Clinical Trial Of AB-1001 For Prevention Of Emesis Associated With Chemo- And Radiation Therapy
2/1/2006 10:34:14 AM
More...
|
Abeille Pharmaceuticals, Inc. Appoints Scientific Advisory Committee
11/14/2005 11:16:13 AM
More...
|
Abeille Pharmaceuticals, Inc. Completes $1.0 Million Preferred Stock Financing; Company To Advance Development Of Lead Products, Enhance Pipeline
10/19/2005 5:12:47 PM
More...
|
Abeille Pharmaceuticals, Inc. Appoints Two New Members To The Board Of Directors
10/19/2005 5:09:43 PM
More...
|